Literature DB >> 6411170

Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.

H D Breidahl, D J Topliss, J W Pike.   

Abstract

A patient with a macroprolactinoma was treated with bromocriptine 15 mg daily. Both the size of the tumour as shown by computed tomography and the serum prolactin concentration decreased over several months but then increased. The dose of bromocriptine was increased to 40 mg daily but tumour growth continued, and the tumour was resected. Production of prolactin by cultured cells was not inhibited by high concentrations of bromocriptine, suggesting that regrowth of the tumour was due to cells resistant to dopamine agonist action. This case of regrowth of a prolactinoma during bromocriptine treatment after an initial reduction in size indicates the need for close surveillance especially of patients whose serum prolactin concentration fails to fall into the normal range with bromocriptine treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411170      PMCID: PMC1548711          DOI: 10.1136/bmj.287.6390.451

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  6 in total

1.  Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine.

Authors:  M O Thorner; R L Perryman; A D Rogol; B P Conway; R M Macleod; I S Login; J L Morris
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

2.  Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours.

Authors:  L G Sobrinho; M C Nunes; C Calhaz-Jorge; J C Maurício; M A Santos
Journal:  Acta Endocrinol (Copenh)       Date:  1981-01

3.  Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases.

Authors:  D Dallabonzana; B Spelta; G Oppizzi; C Tonon; G Luccarelli; P G Chiodini; A Liuzzi
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

4.  Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.

Authors:  P Chiodini; A Liuzzi; R Cozzi; G Verde; G Oppizzi; D Dallabonzana; B Spelta; F Silvestrini; G Borghi; G Luccarelli; E Rainer; R Horowski
Journal:  J Clin Endocrinol Metab       Date:  1981-10       Impact factor: 5.958

5.  Bromocriptine in management of large pituitary tumours.

Authors:  J A Wass; J Williams; M Charlesworth; D P Kingsley; A M Halliday; I Doniach; L H Rees; W I McDonald; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

6.  Effects of bromocriptine on pituitary tumour size.

Authors:  A M McGregor; M F Scanlon; R Hall; K Hall
Journal:  Br Med J       Date:  1979-09-22
  6 in total
  12 in total

1.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Hyperprolactinaemia.

Authors:  T H Jones; R L Kennedy
Journal:  BMJ       Date:  1988-11-12

Review 3.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

Review 4.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 5.  Prolactinomas.

Authors:  A Grossman; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

6.  Hormone-active intradural spinal metastasis of a prolactinoma--a case report.

Authors:  R Landgraf; G Rieder; P Schmiedek; D Clados; K Bise; K von Werder
Journal:  Klin Wochenschr       Date:  1985-04-15

7.  Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?

Authors:  Abdulrahman G Alkabbani; Sann Y Mon; Betul Hatipoglu; Laurence Kennedy; Charles Faiman; Robert J Weil; Amir H Hamrahian
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

Review 8.  Diagnosis and drug therapy of prolactinoma.

Authors:  E Ciccarelli; F Camanni
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 9.  Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.

Authors:  L A Behan; M S Draman; C Moran; T King; R K Crowley; E P O'Sullivan; D Smith; C J Thompson; A Agha
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

10.  Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment.

Authors:  Anne de Bray; Zaki K Hassan-Smith; Jamal Dirie; Edward Littleton; Swarupsinh Chavda; John Ayuk; Paul Sanghera; Niki Karavitaki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.